Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 16/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30025627 | 0.91 | AOC3 (0.84) | AOC3KCNH2 | |
| SCHEMBL30026855 | 0.91 | AOC3 (1.00) | AOC3KCNH2 | |
| SCHEMBL16048225 | 0.91 | AOC3 (0.84) | AOC3KCNH2 | |
| SCHEMBL16048253 | 0.91 | AOC3 (1.00) | AOC3KCNH2 | |
| SCHEMBL17611219 | 0.88 | AOC3 (0.79) | AOC3KCNH2 | |
| SCHEMBL16048998 | 0.83 | AOC3 (1.00) | AOC3KCNH2 | |
| SCHEMBL30026186 | 0.83 | AOC3 (1.00) | AOC3KCNH2 | |
| SCHEMBL17611226 | 0.82 | AOC3 (0.79) | AOC3KCNH2 | |
| SCHEMBL17624697 | 0.81 | AOC3 (0.67) | AOC3KCNH2 | |
| SCHEMBL17611154 | 0.80 | AOC3 (0.79) | AOC3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10968223-B2 | Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors | PROXIMAGEN, LLC (US) | 2021-04-06 | — | — | US | claimed |
| US-20200347059-A1 | IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS | PROXIMAGEN, LLC (US) | 2020-11-05 | — | — | US | claimed |
| US-20200147059-A1 | NEW THERAPEUTIC USES OF ENZYME INHIBITORS | PROXIMAGEN, LLC (US) | 2020-05-14 | — | — | US | claimed |
| EP-3634393-A1 | INHIBITORS OF VASCULAR ADHESION PROTEIN-1 FOR USE IN PREVENTION OR TREATMENT OF MIGRAINE | PROXIMAGEN, LLC (US) | 2020-04-15 | — | — | EP | claimed |
| US-10428066-B2 | Imidazo[4,5-C]pyridine and pyrrolo[2,3-C]pyridine derivatives as SSAO inhibitors | PROXIMAGEN, LLC (US) | 2019-10-01 | — | — | US | claimed |
| EP-2970260-B1 | IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS | PROXIMAGEN LLC (US) | 2019-04-24 | — | — | EP | claimed |
| WO-2018224837-A1 | INHIBITORS OF VASCULAR ADHESION PROTEIN-1 FOR USE IN PREVENTION OR TREATMENT OF MIGRAINE | Proximagen Group Limited (GB) | 2018-12-13 | — | — | WO | claimed |
| US-10968223-B2 | Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors | PROXIMAGEN, LLC (US) | 2021-04-06 | — | — | US | disclosed |
| EP-3777846-A1 | VAP-1 INHIBITORS FOR TREATING PAIN | BenevolentAI Cambridge Limited (GB) | 2021-02-17 | — | — | EP | disclosed |
| EP-3777846-A1 | VAP-1 INHIBITORS FOR TREATING PAIN | BenevolentAI Cambridge Limited (GB) | 2021-02-17 | — | — | EP | disclosed |
| US-20200397764-A1 | VAP-1 INHIBITORS FOR TREATING PAIN | PROXIMAGEN, LLC | 2020-12-24 | — | — | US | disclosed |
| US-20200397764-A1 | VAP-1 INHIBITORS FOR TREATING PAIN | PROXIMAGEN, LLC | 2020-12-24 | — | — | US | disclosed |
| US-20200347059-A1 | IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS | PROXIMAGEN, LLC (US) | 2020-11-05 | — | — | US | disclosed |
| US-20160101072-A1 | Therapeutic uses of enzyme inhibitors | PROXIMAGEN LIMITED (GB) | 2016-04-14 | — | — | US | disclosed |
| US-20160101072-A1 | Therapeutic uses of enzyme inhibitors | PROXIMAGEN LIMITED (GB) | 2016-04-14 | — | — | US | disclosed |
| US-20160046622-A1 | IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS | PROXIMAGEN, LLC | 2016-02-18 | — | — | US | disclosed |
| WO-2015189534-A1 | VAP-1 INHIBITORS FOR TREATING MUSCULAR DYSTROPHY | PROXIMAGEN LIMITED (GB) | 2015-12-17 | — | — | WO | disclosed |
| US-20150258101-A1 | NEW COMPOUNDS | PROXIMAGEN LIMITED (GB) | 2015-09-17 | — | — | US | disclosed |
| US-20150258101-A1 | NEW COMPOUNDS | PROXIMAGEN LIMITED (GB) | 2015-09-17 | — | — | US | disclosed |
| US-20150258101-A1 | NEW COMPOUNDS | PROXIMAGEN LIMITED (GB) | 2015-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200397764-A1 | VAP-1 INHIBITORS FOR TREATING PAIN | VAPB, VAPA, OPRL1 | AOC3 55/4885KCNH2 1764/4885MAPK1 1720/4885 |
| US-10428066-B2 | Imidazo[4,5-C]pyridine and pyrrolo[2,3-C]pyridine derivatives as SSAO inhibitors | PNPO, SSB, XDH | AOC3 10/4885KCNH2 364/4885MAPK1 2405/4885 |
| US-10968223-B2 | Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors | PNPO, PPOX, SCO2 | AOC3 7/4885KCNH2 448/4885MAPK1 1097/4885 |
| US-20200347059-A1 | IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS | PNPO, PPOX, SCO2 | AOC3 7/4885KCNH2 448/4885MAPK1 1097/4885 |
| US-20160046622-A1 | IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS | PNPO, AOC3, IL4I1 | AOC3 2/4885KCNH2 570/4885MAPK1 646/4885 |
| US-20200147059-A1 | NEW THERAPEUTIC USES OF ENZYME INHIBITORS | VAPB, VAPA, SMOX | AOC3 4/4885KCNH2 1505/4885MAPK1 2404/4885 |
| US-20150258101-A1 | NEW COMPOUNDS | AOX1, QSOX1, MAOB | AOC3 85/4885KCNH2 2492/4885MAPK1 4075/4885 |
| US-20160101072-A1 | Therapeutic uses of enzyme inhibitors | VAPB, VAPA, AOX1 | AOC3 21/4885KCNH2 3480/4885MAPK1 3607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.